RBBP6 and cancer: from molecular mechanisms to clinical implications

Résumé

Retinoblastoma binding protein 6 (RBBP6) is a 200 kDa E3 ubiquitin ligase that performs several biological functions and plays a role in tumorigenesis. RBBP6 is overexpressed in several types of tumors, including lung, colorectal, breast, cervical, hepatocellular, and esophageal cancers, suggesting its association with malignant progression. Moreover, this increased expression has been associated with clinicopathological parameters in lung, colorectal, cervical, and ovarian cancers. This review captures the molecular functions of RBBP6 and the mechanisms by which aberrant RBBP6 expression and function influence cancer development and therapeutic response. These mechanisms include its ability to interact with E3 ligase substrates, Jun N-terminal kinase (JNK), noncoding RNAs, and DNA damage-associated proteins to promote cell proliferation, stemness, cell cycle progression, and metastasis. We also evaluated the prognostic and predictive significance of RBBP6 as a potential cancer biomarker and its suitability as a molecular target in cancer. This is the first review that comprehensively explores the multifaceted molecular mechanisms by which RBBP6 influences cancer progression in several cancer types.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0